Clinical Trials Logo
  1. Home
  2. Central Serous Chorioretinopathy
  3. NCT01633983

Methotrexate for Central Serous Chorioretinopathy Treatment Trial — MTX4CSC  

Central Serous Chorioretinopathy Clinical Trial

Official title:
Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy

Clinical Trial Summary

Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may be beneficial in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision.

Clinical Trial Description

Central serous chorioretinopathy (CSC) is a disease of unknown origin usually affecting the center of the macula in adults of working age. Though previously the condition was considered stress-related, multiple recent reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may downregulate the endogenous steroids thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. Few short retrospective series of beneficial effect of MTX on CSC were reported recently. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision in a prospective manner. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01633983
Study type Interventional
Source Hadassah Medical Organization
Contact
Status Not yet recruiting
Phase Phase 2
Start date August 2012
Completion date July 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT03497000 - Effects of OCTA-guided PDT in Acute CSC N/A
Recruiting NCT03692169 - The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
Not yet recruiting NCT02215330 - A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Phase 2/Phase 3
Completed NCT01971190 - Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Phase 2
Completed NCT01990677 - Eplerenone for the Treatment of Central Serous Chorioretinopathy N/A
Active, not recruiting NCT01710332 - The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Phase 2
Active, not recruiting NCT00403884 - Selective RPE Laser Treatment (SRT) for Various Macular Diseases N/A
Recruiting NCT05570591 - Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy N/A
Recruiting NCT05589974 - Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Completed NCT05104138 - Eplerenone Versus PDT: Comparative Study by OCTA
Completed NCT01880788 - Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD N/A
Terminated NCT01982383 - Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy N/A
Completed NCT01019668 - Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy N/A
Completed NCT01327170 - Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy N/A
Recruiting NCT06346405 - Central Serous Chorioretinopathy and Micropulse Laser Treatment
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01822561 - Eplerenone for Central Serous Chorioretinopathy Phase 2
Completed NCT00802906 - Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) N/A
Withdrawn NCT05679180 - Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE N/A
Completed NCT05686421 - Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations N/A